Intellia Therapeutics: Q3 Earnings Report Puts Phase II Results In Focus
Intellia Therapeutics(NTLA) Seeking Alpha·2024-11-11 21:30
Brendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups prior to co-founding 1200 Pharma at the California Institute of Technology (Caltech, 2016).-Became the first employee of 1200 Pharma as it spun out of Caltech garnering major investment (into the 8 figures)-Remains an avid investor, focused on market trends and especially biotechnology stocks ...